Invasive Pneumococcal Disease in New Zealand, 2010
Invasive Pneumococcal Disease in New Zealand, 2010 Invasive Pneumococcal Disease in New Zealand, 2010
Appendix 14. Serotypes among penicillin resistant, cefotaxime resistant and intermediate,and multiresistant isolates from invasive pneumococcal disease cases, 2010Number (% 1 ) isolatesSerotypePenicillin Cefotaximeresistant 2MIC 0.12 mg/L(n=93)intermediate 2MIC 1 mg/L(n=32)resistant 2MIC 2 mg/L(n=10)Multiresistant3(n=28)Serotypes in PCV-7:4 0 0 0 06B 12 (12.9) 4 (12.5) 0 5 (17.9)9V 30 (32.3) 11 (34.4) 0 014 13 (14.0) 9 (28.1) 1 (10.0) 2 (7.1)18C 0 0 0 019F 18 (19.4) 4 (12.5) 9 (90.0) 14 (50.0)23F 2 (2.2) 0 0 1 (3.6)Total for PCV-7 serotypes 75 (80.7) 28 (87.5) 10 (100.0) 22 (78.6)Additional serotypes in PCV-10:1 1 (1.1) 0 0 05 0 0 0 07F 0 0 0 0Total for PCV-10 serotypes 76 (81.7) 28 (87.5) 10 (100.0) 22 (78.6)Additional serotypes in PCV-13:3 0 0 06A 1 (1.1) 1 (3.1) 0 1 (3.6)19A 10 (10.8) 3 (9.4) 0 4 (14.3)Total for PCV-13 serotypes 87 (93.6) 32 (100.0) 10 (100.0) 27 (96.4)Non-PCV serotypes:6C 1 (1.1) 0 0 09 non-typable 1 (1.1) 0 0 011A 1 (1.1) 0 0 0Non-typable 3 (3.2) 0 0 1 (3.6)1 Percentage of the intermediate or resistant isolates.2 Meningitis interpretations; no intermediate category for penicillin.3 Resistant to penicillin (meningitis interpretation) and three additional antibiotics.Invasive pneumococcal disease 40 September 2011in NZ, 2010
Appendix 15. Trends in penicillin resistance, cefotaxime resistance and multidrug resistance amongserotype 19A pneumococci from invasive disease, 2001-2010 1YearNumber ofisolatesPenicillinresistant 2Cefotaximeresistant 3 Multiresistant 4Number Percent (95% CIs) Number Percent (95% CIs) Number Percent (95% CIs)2001 23 7 30.4 (13.2-52.9) 0 0.0 (0.0-14.8) 0 0.0 (0.0-14.8)2002 18 3 16.7 (3.6-41.4) 0 0.0 (0.0-18.5) 0 0.0 (0.0-18.5)2003 22 6 27.3 (10.7-50.2) 1 4.6 (0.1-22.8) 1 4.6 (0.1-22.8)2004 23 6 26.1 (10.2-48.4) 1 4.4 (0.1-21.9) 1 4.4 (0.1-21.9)2005 27 2 7.4 (0.9-24.3) 0 0.0 (0.0-12.7) 0 0.0 (0.0-12.7)2006 27 6 22.2 (8.6-42.3) 0 0.0 (0.0-12.7) 0 0.0 (0.0-12.7)2007 30 3 10.0 (2.1-26.5) 0 0.0 (0.0-11.6) 1 3.3 (0.1-17.2)2008 40 10 25.0 (12.7-41.2) 1 2.5 (0.1-13.2) 3 7.5 (1.6-20.4)2009 37 3 8.1 (1.7-21.9) 0 0.0 (0.0-9.5) 0 0.0 (0.0-9.5)2010 54 10 18.5 (9.3-31.4) 0 0.0 (0.0-6.6) 4 7.4 (2.1-17.9)1 There were no significant differences (P≤0.05) in penicillin, cefotaxime or multidrug resistanceover the 10 year period.2 Penicillin resistant using meningitis interpretations, that is, MIC ≥0.12 mg/L.3 Cefotaxime resistant using meningitis interpretations, that is, MIC ≥2 mg/L.4 Resistant to penicillin (meningitis interpretation) and three additional antibiotics.Invasive pneumococcal disease 41 September 2011in NZ, 2010
- Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
- Page 3 and 4: DISCLAIMERThis report or document (
- Page 5 and 6: CONTENTSSUMMARY ...................
- Page 7 and 8: SUMMARYA 4-dose schedule of the 7-v
- Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
- Page 11 and 12: Data analyses were performed with S
- Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
- Page 15 and 16: The all-age rate of IPD in 2010 (12
- Page 17: 3.4 Disease incidence by ethnicityT
- Page 20 and 21: 3.7 Risk factors among IPD casesThe
- Page 23 and 24: 3.10 Serotype distributionTable 9.
- Page 25 and 26: Rate per 100 000The rate of disease
- Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
- Page 29 and 30: Percent of penicillin-resistant iso
- Page 31 and 32: type most frequently reported to ha
- Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
- Page 35 and 36: Appendix 1. Laboratory criteria upo
- Page 37 and 38: Appendix 3. Rates of invasive pneum
- Page 39 and 40: Appendix 5.2010Risk factors among i
- Page 41 and 42: Appendix 7. Serotypes among invasiv
- Page 43 and 44: Appendix 9. Serotype 1 invasive pne
- Page 45 and 46: Appendix 11. Trends in penicillin r
- Page 47: Appendix 13. Penicillin and cefotax
Appendix 14. Serotypes among penicill<strong>in</strong> resistant, cefotaxime resistant and <strong>in</strong>termediate,and multiresistant isolates from <strong>in</strong>vasive pneumococcal disease cases, <strong>2010</strong>Number (% 1 ) isolatesSerotypePenicill<strong>in</strong> Cefotaximeresistant 2MIC 0.12 mg/L(n=93)<strong>in</strong>termediate 2MIC 1 mg/L(n=32)resistant 2MIC 2 mg/L(n=10)Multiresistant3(n=28)Serotypes <strong>in</strong> PCV-7:4 0 0 0 06B 12 (12.9) 4 (12.5) 0 5 (17.9)9V 30 (32.3) 11 (34.4) 0 014 13 (14.0) 9 (28.1) 1 (10.0) 2 (7.1)18C 0 0 0 019F 18 (19.4) 4 (12.5) 9 (90.0) 14 (50.0)23F 2 (2.2) 0 0 1 (3.6)Total for PCV-7 serotypes 75 (80.7) 28 (87.5) 10 (100.0) 22 (78.6)Additional serotypes <strong>in</strong> PCV-10:1 1 (1.1) 0 0 05 0 0 0 07F 0 0 0 0Total for PCV-10 serotypes 76 (81.7) 28 (87.5) 10 (100.0) 22 (78.6)Additional serotypes <strong>in</strong> PCV-13:3 0 0 06A 1 (1.1) 1 (3.1) 0 1 (3.6)19A 10 (10.8) 3 (9.4) 0 4 (14.3)Total for PCV-13 serotypes 87 (93.6) 32 (100.0) 10 (100.0) 27 (96.4)Non-PCV serotypes:6C 1 (1.1) 0 0 09 non-typable 1 (1.1) 0 0 011A 1 (1.1) 0 0 0Non-typable 3 (3.2) 0 0 1 (3.6)1 Percentage of the <strong>in</strong>termediate or resistant isolates.2 Men<strong>in</strong>gitis <strong>in</strong>terpretations; no <strong>in</strong>termediate category for penicill<strong>in</strong>.3 Resistant to penicill<strong>in</strong> (men<strong>in</strong>gitis <strong>in</strong>terpretation) and three additional antibiotics.<strong>Invasive</strong> pneumococcal disease 40 September 2011<strong>in</strong> NZ, <strong>2010</strong>
Change language